Paulson Wealth Management Inc. boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,712 shares of the company’s stock after buying an additional 115 shares during the period. Paulson Wealth Management Inc.’s holdings in Johnson & Johnson were worth $702,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. Capital World Investors boosted its stake in Johnson & Johnson by 182.9% during the first quarter. Capital World Investors now owns 21,195,989 shares of the company’s stock worth $2,779,435,000 after buying an additional 13,703,905 shares during the last quarter. Nordea Investment Management AB raised its position in Johnson & Johnson by 88.0% in the second quarter. Nordea Investment Management AB now owns 17,222,162 shares of the company’s stock valued at $2,382,514,000 after purchasing an additional 8,062,204 shares during the period. Capital International Investors raised its position in Johnson & Johnson by 13.6% in the first quarter. Capital International Investors now owns 16,726,965 shares of the company’s stock valued at $2,193,411,000 after purchasing an additional 2,004,688 shares during the period. The Manufacturers Life Insurance Company raised its position in Johnson & Johnson by 25.4% in the first quarter. The Manufacturers Life Insurance Company now owns 6,277,296 shares of the company’s stock valued at $823,143,000 after purchasing an additional 1,270,196 shares during the period. Finally, BlackRock Inc. raised its position in Johnson & Johnson by 0.6% in the second quarter. BlackRock Inc. now owns 193,714,044 shares of the company’s stock valued at $27,242,005,000 after purchasing an additional 1,168,129 shares during the period. 67.44% of the stock is currently owned by institutional investors.
A number of research firms have commented on JNJ. SVB Leerink restated an “outperform” rating on shares of Johnson & Johnson in a research report on Wednesday, July 15th. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. Raymond James boosted their price objective on Johnson & Johnson from $157.00 to $158.00 and gave the company an “outperform” rating in a report on Friday, July 17th. Zacks Investment Research downgraded Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price objective on the stock. in a report on Tuesday, July 7th. Finally, Bank of America reiterated a “buy” rating on shares of Johnson & Johnson in a report on Monday, July 20th. One analyst has rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating to the company. Johnson & Johnson has a consensus rating of “Buy” and an average target price of $164.93.
JNJ opened at $148.10 on Friday. Johnson & Johnson has a 12 month low of $109.16 and a 12 month high of $157.00. The stock has a market capitalization of $389.92 billion, a price-to-earnings ratio of 23.29, a PEG ratio of 3.36 and a beta of 0.68. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.25 and a quick ratio of 0.99. The business has a fifty day moving average price of $148.57 and a 200 day moving average price of $146.59.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Sunday, October 18th. The company reported $2.20 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.98 by $0.22. The firm had revenue of $21.08 billion during the quarter, compared to analysts’ expectations of $20.15 billion. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. Johnson & Johnson’s revenue for the quarter was up 1.7% on a year-over-year basis. During the same period in the previous year, the firm posted $2.12 EPS. On average, research analysts anticipate that Johnson & Johnson will post 8 earnings per share for the current year.
In other news, EVP Kathryn E. Wengel sold 16,115 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the transaction, the executive vice president now directly owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Ashley Mcevoy sold 29,000 shares of the company’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total value of $4,276,630.00. Following the transaction, the executive vice president now directly owns 21,682 shares of the company’s stock, valued at $3,197,444.54. The disclosure for this sale can be found here. Corporate insiders own 0.27% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Further Reading: Outstanding Shares, Buying and Selling Stocks
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.